New emerging applications of molgramostim in acute myeloid leukaemia

Bibliography

• Carnot P, Deflandre C. Sur l'activité hématopoïétique du sérum au cours de la régénération du sang. CR Acad Sci 1906;143:432-5
   Google Scholar
• Metcalf D. The molecular control of cell division, differentiation commitment and maturation of haematopoietic cells. Nature 1989;339:27-30
   PubMed Web of Science ®Google Scholar
• Metcalf D. The granulocyte-macrophage colony-stimulating factors. Science 1985;229:16-22
   PubMed Web of Science ®Google Scholar
• Grant SM, Neel RC. Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF). Drugs 1992;43:516-61
   PubMed Web of Science ®Google Scholar
• Cantrell MA, Anderson D, Cerretti DP, et al. Cloning, sequence, and expression of the human granulocyte-macrophage colony-stimulating factor. Proc Natl Acad Sci USA 1985;82:6250-4
   PubMed Web of Science ®Google Scholar
• Wong GG, Witek JS, Temple PA, et al. Human GM-CSF: Molecular coloning of the complementary DNA and purification of the natural and recombinant proteins. Science 1985;228:810-5
   PubMed Web of Science ®Google Scholar
• Burgess AW, Begley CG, Johnson GR, et al. Purification and proporties of bacterially synthesized human granulocyte-macrophage colony-stimulating factor. Blood 1987;69:43-51
   PubMed Web of Science ®Google Scholar
• Hussein AM, Ross M, Vredenburgh J, et al. Effects of granulocyte-macrophage colony-stimulating factor produced in Chinese hamster ovary cells (regramostim), Escherichia coli (molgramostim) and yeast (sargramostim) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Eur J Haematol 1995;55:348-56
   PubMedGoogle Scholar
• Dranoff G, Crawford AD, Sadelain M, et al. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science 1994;264:713-6
   PubMed Web of Science ®Google Scholar
• Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N Engl J Med 1992;327:99-106
   PubMed Web of Science ®Google Scholar
• Sung L, Nathan PC, Lange B, et al. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials. J Clin Oncol 2004;22:3350-6
   PubMed Web of Science ®Google Scholar
• Gerhartz HH, Engelhard M, Meusers P, et al. Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas. Blood 1993;82:2329-39
   PubMed Web of Science ®Google Scholar
• Powles R, Smith C, Milan S, et al. Human recombinant GM-CSF in allogeneic bone-marrow transplantation for leukemia: double-blind, placebo-controlled trial. Lancet 1990;336:1417-20
   PubMed Web of Science ®Google Scholar
• Rabinowe SN, Neuberg D, Bierman PJ, et al. Long-term follow-up of a phase III study of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid malignancies. Blood 1993;81:1903-8
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Suciu S, Archimbaud E, et al. Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group. Blood 1997;90:2952-61
   PubMed Web of Science ®Google Scholar
• Rowe JM, Andersen JW, Mazza JJ, et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 1995;86:457-62
   PubMed Web of Science ®Google Scholar
• Stone RM, Berg DT, George SL, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med 1995;332:1671-7
   PubMed Web of Science ®Google Scholar
• Zittoun R, Suciu S, Mandelli F, et al. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol 1996;14:2150-9
   PubMed Web of Science ®Google Scholar
• Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205
   PubMed Web of Science ®Google Scholar
• Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006;42:2433-53
   PubMed Web of Science ®Google Scholar
• Crawford J, Althaus B, Armitage J, et al. Myeloid growth factors clinical practice guidelines in oncology. J Natl Compr Cancer Netw 2005;3:540-55
   PubMedGoogle Scholar
• Peters WP, Rosner G, Ross M, et al. Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993;81:1709-19
   PubMed Web of Science ®Google Scholar
• Wormann B, Reuter C, Zuhlsdorf M, et al. Experimental basis for the use of recombinant human granulocyte-macrophage colony-stimulating factor in patients with acute myeloid leukemia. Semin Oncol 1994;6:39-43
   Google Scholar
• Kopf B, De Giorgi U, Vertogen B, et al. A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization. Bone Marrow Transplant 2006;38:407-12
   PubMed Web of Science ®Google Scholar
• Winter JN, Lazarus HM, Rademaker A, et al. Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells. J Clin Oncol 1996;14:277-86
   PubMed Web of Science ®Google Scholar
• Cebon JS, Bury RW, Lieschke GJ, et al. The effects of dose and route of administration on the pharmacokinetics of granulocyte-macrophage colony-stimulating factor. Eur J Cancer 1990;26:1064-9
   PubMed Web of Science ®Google Scholar
• Lieschke GJ, Cebon J, Morstyn G. Characterization of the clinical effects after the first dose of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1989;74:2634-43
   PubMed Web of Science ®Google Scholar
• Dorr RT. Clinical properties of yeast-derived versus Escherichia coli-derived granulocyte-macrophage colony-stimulating factor. Clin Ther 1993;15:19-29
   PubMed Web of Science ®Google Scholar
• Zimmer BM, Berdel WE, Ludwig WD, et al. Fatal spleen rupture during induction chemotherapy with rhGM-CSF priming for acute monocytic leukemia. Clinical case report and in vitro studies. Leuk Res 1993;17:277-83
   PubMed Web of Science ®Google Scholar
• Jubinsky PT, Laurie AS, Nathan DG, et al. Expression and function of the human granulocyte-macrophage colony-stimulating factor receptor a subunit. Blood 1994;12:4174-85
   Google Scholar
• Lanza F, Rigolin GM, Castagnari B, et al. Potential clinical applications of rhGM-CSF in acute myeloid leukemia based on its biologic activity and receptor interaction. Haematologica 1997;82:239-45
   PubMedGoogle Scholar
• Tafuri A, Andreef M. Kinetic rational for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia 1990;12:826-34
   Google Scholar
• Griffin JD, Lowenberg B. Clonogenic cells in acute myeloblastic leukemia. Blood 1986;68:1185-95
   PubMed Web of Science ®Google Scholar
• Guan Y, Hogge DE. Proliferative status of primitive hematopoietic progenitors from patients with acute myelogenous leukemia (AML). Leukemia 2000;14:2135-41
   PubMed Web of Science ®Google Scholar
• Cannistra SA, Groshek P, Griffin JD. Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia. Leukemia 1989;3:328-34
   PubMed Web of Science ®Google Scholar
• Reuter C, Auf Der Landwehr U, Schleyer E, et al. Modulation of intracellular metabolism of cytosine arabinoside in acute myeloid leukemia by granulocyte-macrophage colony-stimulating factor. Leukemia 1994;8:217-25
   PubMed Web of Science ®Google Scholar
• Ben-Ishay Z, Prindull G, Sharon S. Improved prognosis in mice with advanced myeloid leukemia following administration of GM-CSF and cytosine arabinoside. Leuk Res 1991;15:321-5
   PubMed Web of Science ®Google Scholar
• Bettelheim P, Valent P, Andreeff M, et al. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood 1991;77:700-11
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Boogaerts MA, Daenen SM, et al. Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol 1997;15:3496-506
   PubMed Web of Science ®Google Scholar
• Hast R, Hellstrom-Lindberg E, Ohm L, et al. No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic sundromes: better outcome in patients with less proliferative disease. Leukemia 2003;17:1827-33
   PubMed Web of Science ®Google Scholar
• Heil G, Chadid L, Hoelzer D, et al. GM-CSF in a double-blind rendomized placebo controlled trial in therapy of adult patients with de novo acute myeloid leukemia (AML). Leukemia 1995;9:3-9
   PubMed Web of Science ®Google Scholar
• Rowe JM, Neuberg D, Friedenberg W, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004;103:479-85
   PubMed Web of Science ®Google Scholar
• Lofgren C, Paul C, Astrom M, et al. Granulocyte-macrophage colony-stimulating factor to increase efficacy of mitoxantrone, etoposide and cytarabine in previously untreated elderly patients with acute myeloid leukaemia: a Swedish multicentre randomized trial. Br J Haematol 2004;124:474-80
   PubMed Web of Science ®Google Scholar
• Uyl-De-Groot CA, Lowenberg B, Vellenga E, et al. Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukemia. Br J Haematol 1998;100:629-36
   PubMed Web of Science ®Google Scholar
• Witz F, Sadoun A, Perrin MC, et al. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Blood 1998;91:2722-30
   PubMed Web of Science ®Google Scholar
• Karp JE, Donehower RC, Enterline JP, et al. In vivo cell growth and pharmacologic determinants of clinical response in acute myelogenous leukemia. Blood 1989;73:24-30
   PubMed Web of Science ®Google Scholar
• Archimbaud E, Fenaux P, Reiffers J, et al. Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia. Leukemia 1993;7:372-7
   PubMed Web of Science ®Google Scholar
• Thomas X, Fenaux P, Dombret H, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 trial). Leukemia 1999;13:1214-20
   PubMed Web of Science ®Google Scholar
• Thomas X, Raffoux E, De Botton S, et al. Effect of priming with granulocyte-macrophage colony-stimulating factor (GM-CSF) in younger adults with newly diagnosed acute myeloid leukemia (AML): a trial by the Acute Leukemia French Association (ALFA) group. Leukemia 2007;21:453-61
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Van Putten W, Theobald M, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003;349:743-52
   PubMed Web of Science ®Google Scholar
• Stripecke R, Levine AM, Pullarkat V, et al. Immunotherapy with acute leukemia cells modified into antigen-presenting cells: ex vivo culture and gene transfer methods. Leukemia 2002;16:1974-83
   PubMed Web of Science ®Google Scholar
• Brouwer RE, Van Der Hoorn M, Kluin-Nelemans HC, et al. The generation of dendritic-like cells with increased allostimulatory function from acute myeloid leukemia cells of various FAB subclasses. Hum Immunol 2000;61:565-74
   PubMed Web of Science ®Google Scholar
• Choudhury BA, Liang JC, Thomas EK, et al. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood 1999;93:780-6
   PubMed Web of Science ®Google Scholar
• Kohler T, Plettig R, Wetzstein W, et al. Cytokine-driven differentiation of blats from patients with acute myelogenous and lymphoblastic leukemia into dendritic cells. Stem Cells 2000;18:139-47
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994;179:1109-18
   PubMed Web of Science ®Google Scholar
• Boyer MW, Waller EK, Bray RA, et al. Cytokine upregulation of the antigen presenting function of acute myeloid leukemia cells. Leukemia 2000;14:412-8
   PubMed Web of Science ®Google Scholar
• Arellano ML, Langston A, Winton E, et al. Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience. Biol Blood Marrow Transplant 2007;13:116-23
   PubMed Web of Science ®Google Scholar
• Grigg A, Kannan K, Schwarer AP, et al. Chemotherapy and granulocyte colony stimulating factor-mobilized blood cell infusion followed by interferon-alpha for relapsed malignancy after allogeneic bone marrow transplantation. Intern Med J 2001;31:15-22
   PubMed Web of Science ®Google Scholar
• Cortes J, O'Brien S, Kurzrock R, et al. GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia. Leukemia 1998;12:860-4
   PubMed Web of Science ®Google Scholar
• Kolb HJ, Rank A, Chen X, et al. In-vivo generation of leukaemia-derived dendritic cells. Best Pract Res Clin Haematol 2004;17:439-51
   PubMed Web of Science ®Google Scholar
• Mohty M, Olive D, Gaugler B, et al. Leukemic dendritic cells: potential for therapy and insights towards immune escape by leukemic blasts. Leukemia 2002;16:2197-204
   PubMed Web of Science ®Google Scholar
• Li JM, Waller EK. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 2004;10:540-51
   PubMed Web of Science ®Google Scholar
• Waller EK, Rosenthal H, Lonial S. DC2 effect on survival following allogeneic bone marrow transplantation. Oncology 2002;16:19-26
   PubMed Web of Science ®Google Scholar
• Fischer HG, Frosch S, Reske K, et al. Granulocyte-macrophage colony-stimulating factor activates macrophages derived from bone marrow cultures to synthesis of MHC class II molecules and to augmented antigen presentation function. J Immunol 1988;141:3882-8
   PubMed Web of Science ®Google Scholar
• MacLaughlin P, Liu N, Poindexter N, et al. Rituximab plus GM-CSF (Leukine®) for indolent lymphoma. Ann Oncol 2005;16(Suppl 5):v68
   Google Scholar
• Rossi JF, Lu ZY, Quittet P, et al. Rituximab activity is potentiated by GM-CSF in patients with relapsed follicular lymphoma: results of a phase II study. Blood 2005;106:684a
   Google Scholar
• Inoges S, Rodriguez-Calvillo M, Zabalegui N, et al. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst 2006;98:1292-301
   PubMed Web of Science ®Google Scholar
• Timmerman JM, Czerwinski DK, Davis TA, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002;99:1517-26
   PubMed Web of Science ®Google Scholar
• Lee ST, Jiang YF, Park KU, et al. BiovaxID: a personalized therapeutic cancer vaccine for non-Hodgkin's lymphoma. Expert Opin Biol Ther 2007;7:113-22
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Lee ST, Qin H, et al. Therapeutic lymphoma vaccines: importance of T-cell immunity. Expert Rev Vaccines 2006;5:381-94
   PubMed Web of Science ®Google Scholar
• Richard C, Baro J, Bello-Fernandez C, et al. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) administration after autologous bone marrow transplantation for acute myeloblastic leukemia enhances activated killer cell function and may diminish leukemic relapse. Bone Marrow Transplant 1995;15:721-6
   PubMed Web of Science ®Google Scholar
• Bendall LJ, Kortlepel K, Gottlieb DJ. GM-CSF enhances IL-2-activated natural killer cell lysis of clonogenic AML cells by upregulating target cell expression of ICAM-1. Leukemia 1995;9:677-84
   PubMed Web of Science ®Google Scholar
• Grabstein KH, Urdal DL, Tushinski RJ, et al. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factors. Science 1986;232:506-8
   PubMed Web of Science ®Google Scholar
• Liljefors M, Nilsson B, Mellstedt H, et al. Influence of varying doses of granulocyte-macrophage colony-stimulating factor on pharmacokinetics and antibody-dependent cellular cytotoxicity. Cancer Immunol Immunother 2008;57:379-88
   PubMed Web of Science ®Google Scholar
• Ragnhammar P, Frodin JE, Trotta PP, et al. Cytotoxicity of white blood cells activated by granulocyte-colony-stimulating factor, granulocyte/macrophage-colony-stimulating factor against tumor cells in the presence of various monoclonal antibodies. Cancer Immunol Immunother 1994;39:254-62
   PubMed Web of Science ®Google Scholar
• Dessureault S, Noyes D, Lee D, et al. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease. Ann Surg Oncol 2007;14:869-84
   PubMed Web of Science ®Google Scholar
• Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539-43
   PubMed Web of Science ®Google Scholar
• Stripecke R, Cardoso AA, Pepper KA, et al. Lentiviral vectors for efficient delivery of CD80 and granulocyte-macrophage colony-stimulating factor in human acute lymphoblastic leukemia and acute myeloid leukemia cells to induce antileukemic immune responses. Blood 2000;96:1317-26
   PubMed Web of Science ®Google Scholar
• Buchner T, Hiddeman W, Wormann B, et al. Age and karyotype-dependent effect of GM-CSF multiple course priming in AML. Blood 1996;88:214a
   Web of Science ®Google Scholar
• Zeng Z, Samudio IJ, Munsell M, et al. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol Cancer Ther 2006;5:3113-21
   PubMed Web of Science ®Google Scholar
• Andreeff M, Konoplev S, Wang RY, et al. Massive mobilization of AML cells into circulation by disruption of leukemia/stroma cell interactions using CXCR4 antagonist AMD3100: first evidence in patients and potential for abolishing bone marrow microenvironment-mediated resistance. Blood 2006;108(Suppl 1):171a
   Google Scholar
• Cartee L, Petros WP, Rosner GI, et al. Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study. Cytokine 1995;7:471-7
   PubMed Web of Science ®Google Scholar
• Rowe JM, Rubin A, Mazza JJ, et al. Incidence of infections in adult patients (>55 years) with acute myeloid leukemia treated with yeast-derived GM-CSF (sargramostim): results of a double-blind prospective study by the Eastern Cooperative Oncology Group. In: Hiddemann W, Buchner T, Wormann B, et al., editors. Acute leukemias V: experimental approaches and management of refractory disease. Berlin: Springer-Verlag; 1996. p. 178-84
   Google Scholar
• Tarr PE, Lin R, Mueller EA, et al. Evaluation of tolerability and antibody response after recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and a single dose of recombinant hepatitis B vaccine. Vaccine 1996;14:1199-204
   PubMed Web of Science ®Google Scholar
• Verkade MA, Van De Wetering J, Klepper M, et al. Peripheral blood dendritic cells and GM-CSF as an adjuvant for hepatitis B vaccination in hemodialysis patients. Kidney Int 2004;66:614-21
   PubMed Web of Science ®Google Scholar
• Taglietti M. Vaccine adjuvancy: a new potential area of development for GM-CSF. Adv Exp Med Biol 1995;378:565-9
   PubMedGoogle Scholar
• Pauksen K, Linde A, Hammarstrom V, et al. Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients. Clin Infect Dis 2000;30:342-8
   PubMed Web of Science ®Google Scholar